BJMO - 2022, issue SPECIAL, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
PACIFIC-R is a real-world international observational study evaluating patients with unresectable stage III non-small-cell-lung cancer treated with durvalumab following platinum-based chemoradiation. At the annual BSMO meeting, baseline characteristics and progression-free survival results for the Belgian cohort of this study were presented and contextualised with the PACIFIC-R global population and the durvalumab arm of the phase III PACIFIC trial.
Read moreBJMO - 2022, issue SPECIAL, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
During the supportive care task force meeting, the BSMO supportive care task force introduced three clinical trials they would like to set up in the near future. In addition, new BSMO guidelines on extravasation and anaemia were presented after which the session was closed by Dr. Christel Fontaine (UZ Brussel) with a status update on the supportive care task force activities over the past year.
Read moreBJMO - 2022, issue SPECIAL, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
The breast cancer task force session of the Belgian Society of Medical Oncology (BSMO) annual meeting reviewed the most important recent data on advanced HER2-positive breast cancer and triple negative breast cancer (TNBC). First, Dr. Eline Naert (University Hospital Ghent) discussed the treatment algorithm for advanced HER2-positive breast cancer anno 2022. Prof. Francois Duhoux (UCLouvain) subsequently addressed the current and emergent treatment options for patients with early or locoregional advanced triple-negative breast cancer. Finally, Prof. Christos Sotiriou (Institut Jules Bordet) closed the session by further dissecting the TNBC heterogeneity through molecular profiling and special transcriptomics.
Read moreBJMO - 2021, issue BJMO IO Special, december 2021
J. Blokken PhD, PharmD, T. Feys MBA, MSc
Over the last decade, immunotherapy has become increasingly important as a treatment modality for various solid tumors. Unfortunately, the development of immunotherapy in the treatment of gastro-oesophageal malignancies has been lagging behind. More recently, however, impressive advancements have been made with immune checkpoint inhibitors in gastro-oesophageal cancers, with a long list of clinical trials yielding promising, and potentially practice changing results. This review provides an overview of the topline results of these studies.
Read moreBJMO - volume 15, issue 8, december 2021
J. Blokken PhD, PharmD, T. Feys MBA, MSc
At this year’s ESMO meeting, much of the attention in the field of lung cancer went to early-stage nonsmall cell lung cancer (NSCLC) with interesting results from the Lung Art, COAST, GEMSTONE-301 and IMpower010 trials. For metastatic NSCLC, immunotherapy again walked away with much of the attention. In addition to this, several studies investigated the potential of combining anti-EGFR and anti-angiogenic agents, while others investigated novel targeted agents, including trastuzumab deruxtecan, poziotinib, plinabulin and datopotamab deruxtecan. Finally, we will highlight the most interesting results in other thoracic malignancies, including malignant pleural mesothelioma, extensive-stage small cell lung cancer, thymoma and thymic carcinoma.
(BELG J MED ONCOL 2021;15(8):406–14)
Read moreBJMO - 2021, issue Special, november 2021
T. Feys MBA, MSc, J. Blokken PhD, PharmD
Over the last decade, the introduction of immune checkpoint inhibitors and targeted agents inhibiting BRAF, and MEK signal transduction pathways revolutionised the treatment paradigm for patients with metastatic melanoma. However, to date there is still no consensus on the optimal treatment sequence in BRAF-mutant metastatic melanoma. In the absence of prospective, randomised data, the treatment choice in clinical practice is mainly driven by patient characteristics. More recently, clinical trials are assessing the optimal treatment sequence of targeted therapy and immunotherapy, while other studies are looking into the potential of combining both treatment modalities in first-line.
Read moreBJMO - 2021, issue Special, november 2021
J. Blokken PhD, PharmD, T. Feys MBA, MSc
Over the past decade, researchers have tried to tackle RET-driven cancers with various multikinase inhibitors. However, their efficacy was only modest and came at the cost of significant toxicities, leading to high rates of treatment discontinuation. Therefore, the development of RET-specific inhibitors has become paramount. Recently, the highly selective RET tyrosine kinase inhibitors selpercatinib and pralsetinib have demonstrated high response rates in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer. As brain metastases eventually occur in approximately 50% of patients with RET fusion-positive NSCLC, special attention should go to the intracranial activity of these drugs.
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.